- Home
- GT vs FOLD Comparison
GT vs FOLD Comparison
Compare GT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GT
- FOLD
- Stock Information
- Founded
- GT 1898
- FOLD 2002
- Country
- GT United States
- FOLD United States
- Employees
- GT N/A
- FOLD N/A
- Industry
- GT Automotive Aftermarket
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- GT Consumer Discretionary
- FOLD Health Care
- Exchange
- GT Nasdaq
- FOLD Nasdaq
- Market Cap
- GT 2.5B
- FOLD 2.9B
- IPO Year
- GT N/A
- FOLD 2007
- Fundamental
- Price
- GT $8.66
- FOLD $9.76
- Analyst Decision
- GT Buy
- FOLD Strong Buy
- Analyst Count
- GT 3
- FOLD 8
- Target Price
- GT $13.30
- FOLD $17.00
- AVG Volume (30 Days)
- GT 4.8M
- FOLD 2.1M
- Earning Date
- GT 02-10-2025
- FOLD 02-26-2025
- Dividend Yield
- GT N/A
- FOLD N/A
- EPS Growth
- GT N/A
- FOLD N/A
- EPS
- GT N/A
- FOLD N/A
- Revenue
- GT $19,047,000,000.00
- FOLD $493,671,000.00
- Revenue This Year
- GT N/A
- FOLD $34.80
- Revenue Next Year
- GT N/A
- FOLD $20.83
- P/E Ratio
- GT N/A
- FOLD N/A
- Revenue Growth
- GT N/A
- FOLD 32.58
- 52 Week Low
- GT $7.27
- FOLD $8.79
- 52 Week High
- GT $14.00
- FOLD $14.03
- Technical
- Relative Strength Index (RSI)
- GT 38.84
- FOLD 56.57
- Support Level
- GT $8.22
- FOLD $9.39
- Resistance Level
- GT $9.34
- FOLD $9.80
- Average True Range (ATR)
- GT 0.29
- FOLD 0.25
- MACD
- GT -0.04
- FOLD 0.05
- Stochastic Oscillator
- GT 31.65
- FOLD 87.67
About GT The Goodyear Tire & Rubber Company
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.